Boundless Bio News

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers,

BusinesswireJun 5 07:00 ET

Red Door Community Raises More Than $300,000 at Their Annual Luncheon Celebrating Women Working and Living With Cancer

Free cancer support programs get a boost, and Red Door Community member announces a run NEW YORK, May 17, 2024 /PRNewswire/ -- On Wednesday, May 15, Red Door Community hosted their annual Celebrating

PR NewswireMay 18 14:06 ET

Boundless Bio Inc. Shifts Corporate Updates to IR Website

TipRanksMay 13 07:22 ET

Boundless Bio, Inc. Q1 Loss Climbs

RTTNewsMay 13 07:17 ET

Boundless Bio | 10-Q: Quarterly report

SEC announcementMay 13 07:09 ET · Announcements

Express News | Boundless Bio Inc: First Patient Dosed in Phase 1/2 Starmap Clinical Trial of Bbi-825 in Patients With Tumors With Resistance Gene Amplifications

ReutersMay 13 07:07 ET

Express News | Boundless: Bbi-355 Phase 1/2 Potentiate Clinical Trial Ongoing;Initiated Therapy Combinations for Tumors With Egfr/Fgfr Oncogene Amplifications

ReutersMay 13 07:07 ET

Boundless Bio 1Q Research and Development Expenses $13.1M >BOLD

Boundless Bio 1Q Research and Development Expenses $13.1M >BOLD

Dow JonesMay 13 07:03 ET

Boundless Bio 1Q Loss/Shr $12.27 >BOLD

Boundless Bio 1Q Loss/Shr $12.27 >BOLD

Dow JonesMay 13 07:03 ET

Express News | Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

ReutersMay 13 07:00 ET

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with prev

BusinesswireMay 6 08:00 ET

Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050

USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of...

PR NewswireMay 1 10:05 ET

Boundless Bio Initiated at Outperform by Leerink Partners

Boundless Bio Initiated at Outperform by Leerink Partners

Dow JonesApr 22 15:21 ET

Express News | Leerink Partners Initiates Coverage On Boundless Bio With Outperform Rating, Announces Price Target of $25

Moomoo 24/7Apr 22 15:11 ET

Express News | Guggenheim Initiates Coverage On Boundless Bio With Buy Rating, Announces Price Target of $24

Moomoo 24/7Apr 22 07:18 ET

Analysts' Opinions Are Mixed on These NA Stocks: Boundless Bio Inc. (BOLD) and Solventum Corporation (SOLV)

TipRanksApr 22 06:40 ET

Express News | Boundless Bio Inc : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $25

Moomoo 24/7Apr 22 06:18 ET

Boundless Bio Initiated at Overweight by Piper Sandler

Boundless Bio Initiated at Overweight by Piper Sandler

Dow JonesApr 22 05:30 ET

Boundless Bio Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 50.49% Piper Sandler → $20 Initiates Coverage On → Overweight 12/09/2019 — Evercore ISI Group

BenzingaApr 22 05:18 ET

Express News | Boundless Bio Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $20: Piper Sandler Initiates Coverage With Overweight Rating; Price Target $20

Moomoo 24/7Apr 22 03:34 ET